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Objective: To compare the diagnostic accuracy of dynamic computed tomography (CT) and gadoxetate-enhanced magnetic 
resonance imaging (MRI) for characterization of hepatic lesions by using the Liver Imaging Reporting and Data System (LI-
RADS) in a multicenter, off-site evaluation.
Materials and Methods: In this retrospective multicenter study, we evaluated 231 hepatic lesions (114 hepatocellular 
carcinomas [HCCs], 58 non-HCC malignancies, and 59 benign lesions) confirmed histologically in 217 patients with chronic liver 
disease who underwent both gadoxetate-enhanced MRI and dynamic CT at one of five tertiary hospitals. Four radiologists at 
different institutes independently reviewed all MR images first and the CT images 4 weeks later. They evaluated the major and 
ancillary imaging features and categorized each hepatic lesion according to the LI-RADS v2014. Diagnostic performance was 
calculated and compared using generalized estimating equations.
Results: MRI showed higher sensitivity and accuracy than CT for diagnosing hepatic malignancies; the pooled sensitivities, 
specificities, and accuracies for categorizing LR-5/5V/M were 59.0% vs. 72.4% (CT vs. MRI; p < 0.001), 83.5% vs. 83.9% (p = 
0.906), and 65.3% vs. 75.3% (p < 0.001), respectively. CT and MRI showed comparable capabilities for differentiating between 
HCC and other malignancies, with pooled accuracies of 79.9% and 82.4% for categorizing LR-M, respectively (p = 0.139).
Conclusion: Gadoxetate-enhanced MRI showed superior accuracy for categorizing LR-5/5V/M in hepatic malignancies in 
comparison with dynamic CT. Both modalities had comparable accuracies for distinguishing other malignancies from HCC.
Keywords: Hepatocellular carcinoma; Magnetic resonance imaging; Computed tomography; Contrast media; Data systems; 
Gadolinium ethoxybenzyl DTPA
Received May 29, 2019; accepted after revision August 15, 2019.
This study was supported by a grant from Bayer Korea Ltd. 
Corresponding author: Myeong-Jin Kim, MD, Department of Radiology, Research Institute of Radiological Science, Severance Hospital, 
Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
• Tel: (822) 2228-7400 • Fax: (822) 393-3035 • E-mail: kimnex@yuhs.ac
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Korean J Radiol 2019;20(12):1616-1626
eISSN 2005-8330
https://doi.org/10.3348/kjr.2019.0363
Original Article | Gastrointestinal Imaging
1617
Intraindividual Multicenter Comparison of EOB-MRI and CT for Diagnosing HCC
https://doi.org/10.3348/kjr.2019.0363kjronline.org
2014, 3) both dynamic CT and gadoxetate-enhanced MRI 
performed within 2 months before the pathologic diagnosis, 
and 4) no past history of hepatic malignancy. Of the 2958 
patients who met the inclusion criteria, 287 were excluded 
because they had undergone local ablative treatments (n = 
274), had ruptured HCCs (n = 3), had active extrahepatic 
malignancy (n = 6), or had false-negative biopsy results (n 
= 4). From the remaining 2671 patients, 103 patients with 
117 non-HCC lesions (59 benign lesions and 58 non-HCC 
malignancies) were included; we also randomly selected 
114 patients with 114 HCCs. Our final study population 
consisted of 217 patients with 231 pathologically-confirmed 
hepatic lesions (Fig. 1).
Image Acquisition 
MRI was performed using 1.5T or 3T scanners. The 
protocols included a dual-echo T1-weighted gradient-
recalled echo sequence, moderately and heavily T2-weighted 
turbo spin-echo sequences, dynamic three-dimensional T1-
weighted gradient-recalled echo sequence using gadoxetic 
acid disodium (Primovist, Bayer AG, Berlin, Germany) as 
INTRODUCTION
Current guidelines for the management of hepatocellular 
carcinoma (HCC) allow the diagnosis of HCC in high-risk 
patients without histologic confirmation if a hepatic lesion 
shows typical findings on dynamic contrast-enhanced 
computed tomography (CT) or magnetic resonance imaging 
(MRI) (1-5). However, non-HCC malignancies such as 
intrahepatic cholangiocarcinoma (CCA) or combined HCC-
CCA may also display imaging findings of typical HCCs, 
particularly in small tumors in the cirrhotic liver (6-8). Since 
the treatment options and prognoses are different for non-
HCC malignancies and HCC, imaging-based differentiation of 
HCC and other malignancies is important (9, 10). 
The Liver Imaging Reporting and Data System (LI-
RADS), unlike other diagnostic criteria, addresses the 
issue of imaging diagnosis of non-HCC malignancies (11, 
12). It requires the LR-M category to be assigned to a 
hepatic lesion suspected to be a non-HCC malignancy, and 
recommends histological diagnosis of these LR-M lesions 
(13, 14). 
Although previous studies have compared the LI-RADS 
diagnostic accuracy of gadoxetate-enhanced MRI and 
dynamic CT (15-18), a multicenter study involving off-site 
evaluations by multiple readers has not been performed. 
Therefore, the purpose of this study was to compare the 
diagnostic performance of gadoxetate-enhanced MRI and 
dynamic CT for assessments based on LI-RADS v2014 during 
characterization of focal hepatic lesions in patients with 
chronic liver disease.
MATERIALS AND METHODS
Subjects
This retrospective multicenter study was approved by 
the Institutional Review Boards of all five participating 
institutions, which are academic tertiary hospitals in Korea. 
The requirement for written informed consent for the 
retrospective review of medical records and image data was 
waived.
Investigators from five institutions searched the 
databases to identify patients aged 18 years or older who 
met the following inclusion criteria: 1) at risk of developing 
HCC (hepatitis B virus [HBV] carrier, hepatitis C virus carrier 
with chronic hepatitis, or cirrhosis from any causes), 2) 
pathologic diagnosis of focal hepatic lesions based on 
surgery or biopsy findings between January 2008 and July 
Fig. 1. Flowchart illustrating subject selection. CT = computed 
tomography, HCC = hepatocellular carcinoma, MRI = magnetic 
resonance imaging
2958 potentially eligible patients
- At risk of developing HCC
- Both multidetector CT and gadoxetate-enhanced MRI
-  Pathologically-confirmed hepatic lesions between January 2008 
and July 2014
2671 eligible patients
Final study cohort: 217 patients with 231 lesions
- 114 HCCs, 58 non-HCC malignancies, and 59 benign lesions
103 patients with pathologically-
confirmed non-HCC lesions 2568 patients with HCC
287 were excluded:
-  Treated before imaging or 
surgery (n = 274)
- Ruptured HCCs (n = 3)
- Extrahepatic cancer (n = 6)
-  False-negative biopsy  
(n = 4)
All 103 patients with 117
lesions were included
114 HCC patients were
randomly selected
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the contrast medium, and diffusion-weighted imaging. For 
dynamic imaging, arterial-, portal venous-, transitional-, 
and hepatobiliary-phase images were acquired 25–35 
seconds, 60–70 seconds, 2 or 3 minutes, and 15 or 20 
minutes after contrast injection, respectively. Contrast-
enhanced dynamic CT was performed using 16-, 40-, or 
64-detector scanners. After acquiring unenhanced images, 
arterial-, portal venous-, and delayed-phase images were 
obtained approximately 30 seconds, 70 seconds or 90 
seconds, and 180 seconds or 210 seconds after iodinated 
contrast medium injection, respectively. Technical details 
for CT and MRI acquisition are provided in Supplementary 
Material 1.
Data Collection and Preparation
Clinical, pathologic, and imaging data were retrieved 
from the database of each participating institution, which 
included information about patient demographics, the 
cause of chronic liver disease, serum alpha-fetoprotein 
level, child-Pugh class, pathologic diagnosis, and CT/MR 
images. They were then sent to the central site (Severance 
Hospital), where the image data were anonymized, 
randomized, and assigned new identification numbers. 
The processed imaging data, along with screen-captured 
images marking the lesions’ sites (which was performed by 
an abdominal radiologist with 4 years of experience), were 
then sent back for image analysis. The data collection and 
preparation steps are described in detail in Supplementary 
Material 2.
Image Analysis
Four board-certified abdominal radiologists from different 
institutions (Reviewer 1, Reviewer 2, Reviewer 3, and 
Reviewer 4, with 5, 6, 10, and 21 years of experience, 
respectively, in abdominal CT and MRI) independently 
analyzed the CT/MR images and submitted the results to 
the central site. In the first round, they analyzed the MR 
images to evaluate the LI-RADS features and determine the 
initial LI-RADS category in each case without assessing 
the ancillary features. Then, they evaluated the ancillary 
features and assigned the final LI-RADS category. They did 
not evaluate the presence or absence of threshold growth. 
In the second round conducted at least 8 weeks after the 
first round to minimize recall bias, they evaluated the CT 
images in the same manner. In cases where a hepatic lesion 
could not be delineated in the marked area, it was recorded 
as “not visible” and considered benign. The washout 
appearance was determined twice, first as defined in the 
LI-RADS by using the portal venous phase alone (11, 13, 
14), and then by using both portal- and transitional-phase 
images. The reviewers were asked to characterize a feature 
as absent if they could not unequivocally determine whether 
the feature was present or absent due to suboptimal or poor 
image quality.
A detailed description of the image analysis protocol is 
provided in Supplementary Material 3.
Statistical Analysis
For sample size estimation, the expected per-lesion 
sensitivities of dynamic CT and MRI for HCC were assumed 
to be 68% and 80%, respectively, with the same specificity 
of 94% (19). On the basis of these expected values and a 
power of 80%, we calculated that we would need 209 or 
more hepatic lesions to obtain a significant difference in 
diagnostic performance with a two-sided type I error of 5% 
(20). 
The baseline characteristics were compared using 
analysis of variance for continuous variables and the chi-
squared test for categorical variables. Multiple comparisons 
were corrected using Bonferroni’s method. The frequency 
of image features was compared using chi-squared or 
Fisher’s exact tests. We used a generalized estimating 
equation method to compare the diagnostic performance 
between dynamic CT and MRI for distinguishing hepatic 
malignancies from benign lesions categorized as LR-5, LR-
5V, or LR-M; for differentiating HCC from non-HCC lesions 
categorized as LR-5 or LR-5V; for differentiating non-HCC 
malignancies from other lesions categorized as LR-M; and 
then in subgroups containing only two disease entities 
for differentiating between HCC and benign lesions (with 
other malignancies excluded) and between HCC and other 
malignancies (with benign lesions excluded). In addition, 
we examined the diagnostic performance of LR-5 (without 
LR-5V) for HCC. We used LR-5 alone, not including LR-4, for 
the calculation of diagnostic accuracy, because LR-5 alone 
is considered to indicate “definite HCC” in LI-RADS (11, 
13, 14). Lastly, we calculated the diagnostic performance 
of gadoxetate-enhanced MRI when using the portal phase 
alone for washout evaluation and compared it with the 
results obtained using both the portal and transitional 
phases. Pathologic diagnosis was used as a reference 
standard. To examine the added value of the ancillary 
features, we tabulated the LI-RADS categories before and 
after applying the ancillary features and calculated the 
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RESULTS
Baseline Characteristics, LI-RADS Categories, and Major 
Features
The baseline characteristics of the 217 patients with 231 
hepatic lesions (114 HCCs, 58 other malignancies, and 59 
benign lesions) are summarized in Table 1. Patients with 
other malignancies were significantly older compared to 
those with HCCs (p = 0.017) and benign lesions (p = 0.006). 
HBV was a more common etiology of chronic liver disease 
in patients with HCCs than in those with benign lesions 
(p = 0.003). Tumor size was the largest in patients with 
other malignancies and the smallest in patients with benign 
lesions (p < 0.001), and biopsy was more frequently used 
for the diagnosis of other malignancies or benign lesions 
than HCCs (p < 0.001). The interval between CT and MRI 
ranged from 0 to 64 days, with a median interval of 12 
days. Pathologic diagnosis was performed within 2 months 
after the first imaging study as it was one of our inclusion 
net reclassification improvement. The net reclassification 
improvement is a statistic for assessing the improvement 
in performance gained by adding a new factor to a model 
by measuring the extent to which individual subjects with 
and without disease are appropriately reclassified into more 
appropriate categories (21). We performed this analysis 
only on MRI cases after excluding the LR-M and “not 
visible” cases. Kappa statistics were computed as indices 
of inter-reader agreements between the four readers. Kappa 
statistics were used to indicate agreement, with 0.8–1.0 
indicating excellent agreement; 0.60–0.79, good agreement; 
0.40–0.59, moderate agreement; 0.20–0.39, fair agreement; 
and 0–0.19, poor agreement. All statistical analyses were 
performed using SAS 9.2 (SAS Institute Inc., Cary, NC, 
USA) and R version 3.3.3 (The R Foundation for Statistical 
Computing, Vienna, Austria). P values < 0.05 were 
considered statistically significant. A detailed description 
of our statistical analysis is provided in Supplementary 
Material 4.
Table 1. Baseline Characteristics
Characteristic HCC OM* Benign† P Total
Per-patient basis
Number of patients 114 53 50 217
Median age (range, years) 59 (40–85) 63 (42–76) 55 (36–78) 0.003 59 (36−85)
Sex (%) 0.835
Male 89 (78.1) 40 (75.5) 37 (74.0) 166 (76.5)
Female 25 (21.9) 13 (24.5) 13 (26.0) 51 (23.5)
Cause of chronic liver disease (%) 0.003
HBV 98 (86.8) 38 (71.7) 32 (64.0) 168 (77.9)
HCV 7 (6.1) 2 (3.8) 3 (6.0) 12 (5.5)
HBV/HCV coinfection 0 (0) 1 (1.9) 0 (0) 1 (0.5)
Non-viral 9 (7.0) 12 (22.6) 15 (30.0) 36 (16.1)
Child-Pugh class (%) 0.285
A 102 (89.5) 50 (94.3) 48 (96.0) 200 (92.2)
B 10 (8.8) 3 (5.7) 2 (4.0) 15 (6.9)
C 2 (1.7) 0 (0) 0 (0) 2 (0.9)
Median AFP (range, ng/mL) 9.35 (0.6–50676.0) 4.4 (1.3–1771.0) 3.9 (0.9–55.1) < 0.001 5.5 (0.6−50676.0)
Per-lesion basis
Number of lesions 114 58 59 231
Median size (range, cm) 2.3 (0.5–12.2) 2.8 (0.5–13.2) 1.5 (0.7–7.1) < 0.001 2.1 (0.3−13.3)
Method of diagnosis (%) < 0.001
Biopsy 3 (2.6) 12 (20.7) 22 (37.3) 37 (16.0)
Resection 110 (96.5) 46 (79.3) 35 (59.3) 191 (82.7)
Transplantation 1 (0.9) 0 (0) 2 (3.4) 3 (1.3)
*OM includes 30 intrahepatic cholangiocarcinomas, 15 combined hepatocellular-cholangiocarcinomas, 11 metastases, 1 neuroendocrine 
carcinoma, and 1 lymphoepithelioma-like carcinoma, †Benign lesion includes 29 dysplastic/regenerative nodules, 8 focal nodular 
hyperplasia-like nodules, 8 hemangiomas, 5 angiomyolipomas, 3 bile duct adenomas, 2 adenomas, 2 eosinophilic abscesses,  
1 inflammatory pseudotumor, and 1 tuberculoma. AFP = alpha-fetoprotein, HBV = hepatitis B virus, HCC = hepatocellular carcinoma,  
HCV = hepatitis C virus, OM = other malignancies
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criteria.
The frequencies of HCCs, other malignancies, and benign 
lesions according to the LI-RADS category and imaging 
modality are presented in Figure 2 (only pooled results) 
and Supplementary Table 1 (including full results). Minor 
proportions of non-HCC malignancies were categorized as 
LR-5V (3.4% [8/232] for CT and 4.7% [11/232] for MRI) 
(Figs. 2, 3). 
The frequencies of major features—arterial-phase 
hyperenhancement, washout appearance, and capsule 
appearance—according to imaging modality are presented 
in Supplementary Tables 2 (by disease) and 3 (by size, only 
including HCCs). There were seven cases in which at least 
one reviewer decided that evaluation of arterial-phase MR 
images was suboptimal because of severe motion artifacts 
or too early acquisition. In HCC lesions, diffuse arterial 
hyperenhancement and washout appearance either in the 
portal or transitional phase were more frequently observed 
on MRI than on CT (88.2% vs. 82.5% [p = 0.015] and 90.4% 
vs. 77.2% [p = 0.005], respectively), but the frequency of 
washout appearance observed on MRI became lower than 
that on CT when the washout appearance was determined in 
the portal phase alone (71.1% vs. 77.2% [p = 0.034]). Rim-
like arterial-phase hyperenhancement, a feature favoring 
malignancies other than HCC, was more frequently observed 
on MRI than on CT in non-HCC malignancies (44.8% vs. 
32.3%, p = 0.006), but not in HCC (4.6% vs. 6.8%, p = 
0.205) or benign lesions (7.2% vs. 5.5%, p = 0.572).
Diagnostic Performance of Dynamic CT and MRI
Diagnosis of Hepatic Malignancies 
In the diagnosis of hepatic malignancies, MRI showed 
higher sensitivity and accuracy than CT, but the specificities 
of the two methods were not significantly different (Table 
2 [only pooled results], Supplementary Table 4 [including 
full results], and Fig. 4). With data pooled from all the 
reviewers, the sensitivity, specificity, and accuracy were 
72.4%, 83.9%, and 75.3%, respectively, for MRI, and 
59.0%, 83.5%, and 65.3%, respectively, for CT (p < 0.001 
for sensitivity and accuracy, and p = 0.906 for specificity). 
For differentiation of HCC from non-HCC lesions, MRI 
showed higher sensitivity but lower specificity than CT, and 
accuracy was not significantly different with or without 
including LR-5V in the diagnostic criteria (p > 0.576). 
For differentiation of other malignancies from HCC and 
benign lesions, no significant differences were observed in 
sensitivity, specificity, and accuracy between CT and MRI (p 
= 0.139).
Fig. 2. Frequencies and proportions of HCC, OM, and benign lesions according to imaging modality and Liver Imaging Reporting 
and Data System category. Numbers and areas of segments in each vertical bar indicate numbers and proportions of HCC, OM, and benign 
lesions, respectively. Pooled results from four reviewers are shown here (see Supplementary Table 1 for full results). NV = not visible, OM = other 
malignancies
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pooled results] and Supplementary Table 5 [including full 
results]). Similar results were obtained when LR-5V was not 
considered diagnostic for HCC.
Comparison of the Portal and Delayed Phases for 
Evaluating the Washout Appearance
When the portal phase alone was used for evaluating 
the washout appearance, the pooled results demonstrated 
that the specificity significantly increased (p = 0.049) but 
Analyses of Subgroups Containing Only Two Disease 
Entities
In a subgroup with HCC and benign lesions (other 
malignancies excluded), MRI showed higher sensitivity 
and accuracy than CT for the diagnosis of HCC (with the 
pooled data, 62.5% vs. 52.4% [p = 0.003] and 72.0% vs. 
66.2% [p = 0.019], respectively) with similar specificities 
(90.3% vs. 92.8%, p = 0.352). However, in a subgroup with 
HCC and other malignancies (benign lesions excluded), 
the sensitivity, specificity, and accuracy of MRI and CT 
for discriminating other malignancies from HCC were 
not significantly different (p > 0.150) (Table 3 [only 
Table 2. Diagnostic Performance of CT and Gadoxetate-Enhanced MRI for Hepatic Malignancy 
LR-5/5V/M for Hepatic 
Malignancy
LR-5/5V for HCC LR-5 for HCC
LR-M for Non-HCC 
Malignancies
CT MRI P CT MRI P CT MRI P CT MRI P
TP/TN/ 
FP/FN
406/197/ 
39/282
498/198/ 
38/190
239/424/ 
44/217
285/389/ 
79/171
227/433/ 
35/229
272/402/ 
66/184
117/647/ 
45/115
134/654/ 
38/98
Sensitivity, % 59.0 72.4 < 0.001 52.4 62.5 0.003 49.8 59.7 0.004 50.4 57.8 0.167
Specificity, % 83.5 83.9 0.906 90.6 83.1 0.002 92.5 85.9 0.003 93.5 94.5 0.494
Accuracy, % 65.3 75.3 < 0.001 71.8 72.9 0.576 71.4 72.9 0.468 82.7 85.3 0.139
These are pooled results from four reviewers. Unless otherwise specified, data represent numbers of cases. CT = computed tomography, FN 
= false negative, FP = false positive, MRI = magnetic resonance imaging, TN = true negative, TP = true positive
Fig. 3. Non-HCC malignancy with tumor in vein. Diffuse 
hypervascular tumor with infiltrative margins is seen at right hemi-
liver. Tumor also invades adjacent portal vein branch (P8), forming 
mass within vein (arrows). Two of our four reviewers categorized 
this mass as LR-5V, while other two assigned score of LR-M. 
Pathologic diagnosis obtained after biopsy was combined HCC-
cholangiocarcinoma.
Fig. 4. Pathologically-confirmed HCC categorized as LR-5 
only with gadoxetate-enhanced MRI. 58-year-old female HBV 
carrier underwent both dynamic CT and gadoxetate-enhanced MRI 
with interval of 3 days. Her serum alpha-fetoprotein level was 
elevated at surveillance for HCC. On gadoxetate-enhanced MRI, 
all our reviewers found 1.8-cm nodule in right liver (arrow) with 
arterial hyperenhancement, portal washout appearance, and capsule 
appearance, and categorized this nodule as LR-5. However, on dynamic 
CT, only faint arterial hyperenhancement (arrowhead) was visualized at 
corresponding location. All reviewers categorized lesion as LR-3 or LR-
4. HBV = hepatitis B virus
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sensitivity and accuracy significantly decreased (p < 0.002) 
compared to the findings obtained using both portal and 
transitional phases in the diagnosis of hepatic malignancies 
(Table 4 [only pooled results] and Supplementary Table 
6 [including full results]). However, despite the decrease 
in sensitivity, MRI showed significantly higher sensitivity 
(67.7% vs. 59.0%, p < 0.001) and accuracy (72.5% vs. 
65.3%, p < 0.001) than CT (Table 4). 
Added Value of the Ancillary Features in Gadoxetate-
Enhanced MRI
Analysis of the pooled data revealed that the ancillary 
features modified the final LI-RADS category in 110 (12.0%) 
of 918 cases (Supplementary Table 7). None of the LR-4 
cases was upgraded to LR-5, as it is not warranted by the 
LI-RADS (7). Of the 686 malignant cases, 22 (3.2%) were 
correctly upgraded into higher LI-RADS categories, while 25 
(3.6%) were incorrectly downgraded into lower categories. 
Of the 232 benign cases, 36 (15.5%) and 28 (12.1%) were 
reclassified into higher and lower LI-RADS categories, 
respectively. The overall net reclassification improvement 
was estimated to be -0.055 (p = 0.117), indicating a 
negative impact on the overall categorization without 
statistical significance. However, of 32 and 19 benign cases 
initially categorized as LR-5/5V and LR-M, 10 (31.3%) and 
4 (21.1%), respectively, were correctly downgraded into 
lower categories after applying ancillary features (Fig. 5). 
Inter-Reader Agreement
When the LI-RADS categories were grouped into three 
categories of LR-5/5V, LR-M, and LR-1/2/3/4, inter-reader 
agreements were good for both CT and MRI (κ = 0.626 and 
0.601, respectively). Inter-reader agreements were good 
for arterial hyperenhancement assessments using CT (κ = 
0.675) and moderate MRI (κ = 0.563), for assessments of 
washout appearance by using CT and MRI (κ = 0.510 and 
0.532, respectively), as well as for assessments of capsule 
appearance by using CT (κ = 0.476). However, inter-reader 
agreement was fair for assessments of capsule appearance 
by using MRI (κ = 0.326). 
DISCUSSION
The results of this multicenter, off-site reader study 
showed that gadoxetate-enhanced MRI has higher 
sensitivity and accuracy than CT in discriminating 
between malignant and benign lesions in patients with 
chronic liver disease, as shown in previous studies (19, 
22). However, other recent studies have shown that the 
diagnostic accuracy was comparable between gadoxetate-
Table 3. Diagnostic Performance of CT and Gadoxetate-Enhanced MRI in Differentiation of HCC from Benign Lesions and OM from 
HCC
LR-5/5V for HCC vs. Benign LR-5 for HCC vs. Benign LR-M for HCC vs. OM
CT MRI P CT MRI P CT MRI P
TP/TN/ 
FP/FN
239/219/ 
17/217
285/213/ 
23/171
227/220/ 
16/229
272/215/ 
21/184
117/433/ 
23/115
134/433/ 
23/98
Sensitivity, % 52.4 62.5 0.003 49.8 59.7 0.005 50.4 57.8 0.167
Specificity, % 92.8 90.3 0.352 93.2 91.1 0.398 95.0 95.0 0.999
Accuracy, % 66.2 72.0 0.019 64.6 70.4 0.017 79.9 82.4 0.139
These are pooled results from four reviewers. Unless otherwise specified, data represent numbers of cases. These are results from 
subgroup analysis in differentiation of HCC from benign lesions (with OM excluded from analysis) and OM from HCC (with benign lesions 
excluded from analysis).
Table 4. Diagnostic Performance of Gadoxetate-Enhanced MRI Using PP Alone for Washout Appearnace
(a) CT (b) MRI Using PP and TRP (c) MRI Using PP Alone P
P*
(a) vs. (c)
P*
(b) vs. (c)
TP/TN/FP/FN 406/197/39/282 498/198/38/190 466/204/32/222
Sensitivity, % 59.0 72.4 67.7 < 0.001 < 0.001 < 0.001
Specificity, % 83.5 83.9 86.4 0.119 0.374 0.049
Accuracy, % 65.3 75.3 72.5 < 0.001 < 0.001 0.002
These are pooled results from four reviewers. These results show diagnostic performance of gadoxetate-enhanced MRI when using portal 
phase alone for evaluating washout appearance, in comparison with CT or MRI using both portal and transitional phases in diangosis of 
hepatic malignancies. *p values from post-hoc tests. PP = portal phase, TRP = transitional phase
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In contrast, the accuracy for differentiating HCCs from 
other malignancies was comparable between gadoxetate-
enhanced MRI and CT, as suggested by previous studies 
in which both gadoxetate-enhanced MRI and CT showed 
limitations in accurately discriminating HCC from other 
malignancies, especially combined HCC-CCA (27-30). 
Furthermore, similar to a previous report (27), we noted that 
3.4% (8/232) and 4.7% (11/232) of non-HCC malignancies 
showed tumors in the vein and were categorized as LR-5V 
for CT and MRI, respectively, which further decreased the 
specificity of LR-5/5V for HCC diagnosis. However, the latest 
version (v2018) of LI-RADS has revised LR-5V (definitely 
HCC with tumor in vein [TIV]) to LR-TIV, so the presence 
of the TIV would no longer decrease the specificity for HCC 
diagnosis (31).
We observed that the application of the ancillary features 
modified the LI-RADS categories in 12% (111/924) of cases, 
similar to the results of two recent studies (15.3% and 
18.1%) (12, 25). In our study, no significant improvement 
was observed in the overall LI-RADS categorization with 
addition of the ancillary features. However, 10 benign 
lesions initially categorized as LR-5/5V were correctly 
downgraded (Fig. 5, Supplementary Table 7). Two recent 
studies using extracellular contrast media reported 
conflicting results on the impact of upgrading LR-3 to LR-4 
based on ancillary features on the diagnostic performance 
(12, 32). Both studies showed that the application of 
ancillary features increased the sensitivity of LR-4/5/5V for 
HCC, while the specificity was shown to be preserved in one 
study (12) and decreased in another (32). 
Our study also showed that multicenter, off-site 
evaluations could achieve comparable inter-reader 
agreement for LI-RADS categorization with both MRI and 
CT, as seen in previous single-center studies (33, 34). A 
recent study involving 113 readers from eight different sites 
reported a better inter-reader agreement (35). However, 
in that study, preselected screen-captured images were 
evaluated, in contrast to our study, in which whole series of 
images were provided to the reviewers.
This study had limitations. First, our study may have 
biases due to its retrospective design. There were 
differences in several baseline characteristics between 
patients with malignant and benign lesions in this study, 
which might have resulted in further biases. In addition, 
inclusion of only pathologically-confirmed lesions may have 
been a source of selection bias. For example, most of the 
benign lesions included were likely difficult to diagnose by 
enhanced MRI and CT for the diagnosis and characterization 
of hepatic lesions on the basis of LI-RADS (23-25). In 
comparison with our study, these results were not obtained 
in a multicenter study involving off-site evaluation by 
multiple readers. Furthermore, we included a substantial 
number of cases involving non-HCC malignancies because 
our purpose was to compare the performance of dynamic CT 
and MRI in differential diagnosis. Therefore, we believe that 
the multicenter and multireader study design as well as the 
addition of a sufficient number of non-HCC malignancies 
would be strengths of our study. The higher sensitivity of 
gadoxetate-enhanced MRI in differentiating hepatic lesions 
could be attributed to its superiority in demonstrating 
imaging features favoring malignancies. In line with a 
recently published study (26), we found that arterial 
hyperenhancement as well as washout appearance were 
more frequently observed in HCCs on gadoxetate-enhanced 
MRI than on CT. 
Fig. 5. Benign lesion initially categorized as LR-5 but correctly 
downgraded by applying ancillary features. 52-year-old HBV 
carrier underwent gadoxetate-enhanced MRI after hepatic nodule was 
found on ultrasonography. 1.4-cm nodule in left liver shows arterial 
hyperenhancement (arrow) and washout appearance on portal phase 
(arrow). Two reviewers considered arterial enhancement as rim-like 
and categorized nodule as LR-M. Other reviewers initially categorized 
nodule as LR-5. Nodule shows signal drop from opposed-phase to in-
phase of T1-weighted gradient-recalled echo sequence (arrowhead), 
indicating presence of intralesional iron deposits. Note that nodule 
shows isointensity on T2-weighted image. These features are 
uncommon finding in progressed HCCs. After applying these ancillary 
features, reviewers downgraded their categories to LR-4. This nodule 
was confirmed as angiomyolipoma after hepatic resection.
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imaging alone, which might have affected the diagnostic 
accuracy—most likely by underestimating the specificity. 
However, we believe that the reference standard for 
evaluating the performance during differential diagnosis of 
hepatic tumors must be histopathological findings, since 
some non-HCC malignancies may show the typical imaging 
features of HCCs (8, 23, 28) and these HCC mimickers can 
be treated by locoregional or systemic treatment without 
pathologic confirmation according to the current guidelines 
(28). Second, we used the earlier version of LI-RADS (v2014) 
because it was the latest version available at the time of 
our image analysis. However, except for the change from 
LR-5V to LR-TIV, only minor changes (i.e., mainly more 
elaborate definitions of features) have been made in the 
diagnostic table (12). Furthermore, we obtained similar 
results when only LR-5 was considered positive for HCC 
diagnosis. In addition, since the LI-RADS v2014 did not 
specifically define high-risk patients and advised to follow 
the other guidelines, we also included non-cirrhotic patients 
with chronic hepatitis C according to European Association 
for the Study of the Liver (2). However, the latest version 
(v2018) of LI-RADS does not consider chronic hepatitis C 
patients at risk. Thus, our loose inclusion criteria might 
have affected the results, although the proportion of such 
patients was small (i.e., about 5%). Third, we evaluated 
washout appearance using two methods; by using portal 
phase alone and also by using both portal and transitional 
phases. Using the transitional phase for evaluating 
washout appearance might have led to an overestimation 
of sensitivity of gadoxetate-enhanced MRI. However, we 
also obtained similar results in the supplementary analysis 
performed using the portal phase alone for washout 
evaluation. 
In conclusion, our multicenter off-site evaluation study 
showed that gadoxetate-enhanced MRI was superior to CT 
in differentiating hepatic malignancies from benign lesions 
by using the LI-RADS v2014 in patients with chronic liver 
disease. Both modalities had comparable capabilities for 
distinguishing HCC and other malignancies. The ancillary 
features on gadoxetate-enhanced MRI may help avoid 
misdiagnosis of benign lesions as definitely malignant 
lesions.
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